immPRINT

Challenge

There is a lack of functional biomarkers that directly measure immune fitness and DNA repair ability in research and clinical settings. 70% of severe immune defects go undiagnosed, leading to unnecessarily large clinical trials, preventable complications, and inappropriate treatment. 16% of self-reported healthy are classified as immunodeficient.

Solution

immPRINT uses one assay to evaluate immune system performance and DNA repair capacity, two key determinants of health. This enables versatile applications, including infection risk profiling, cancer risk assessment, vaccine prioritization, and donor stratification based on functional fitness.

Early detection of diseases linked to immune and DNA repair defects
Stable breakpoint signatures along time enable reproducible readouts
Mechanism-based approach independent of causative factors
Compatible with scalable sequencing and clinical workflows

High accuracy

99% accuracy immune defects
84% accuracy DNA repair defects

Highly versatile

Identifying, among others, immune defects and virus reactivation

IP

Long-read sequencing of human immunoglobulin gene introns to define a biomarker for in vivo DNA break repair.
WO2024194255A1
National phases: EP, US, IL